立体定向体部放疗对比射频消融治疗亚洲肝细胞癌患者
这项多国回顾性研究纳入2064例不可切除肝细胞癌患者,比较立体定向体部放疗(SBRT)与射频消融(RFA)的疗效。倾向评分匹配后每组313例,SBRT组局部复发风险显著低于RFA组(匹配队列HR 0.36,p<0.001),急性≥3级毒性两组相当(1.6% vs. 2.6%,p=0.268)。SBRT可作为不可切除HCC的有效替代选择,尤其适用于较大肿瘤、膈下位置或TACE后进展者。
要点
- SBRT组3年局部累积复发率21.2%,低于RFA组的27.9%(p<0.001)。
- 匹配后SBRT局部复发风险显著低于RFA(HR 0.36,p<0.001)。
- 小肿瘤(≤3cm)、膈下大肿瘤及TACE后进展者SBRT局部控制更优。
核心结论
- SBRT可作为不可切除肝细胞癌的有效替代方案,局部控制优于RFA且毒性相当。
- 尤其适用于大于3cm的膈下肿瘤及经TACE治疗后进展的肿瘤。
研究设计与样本
- 多国回顾性队列研究,纳入7家医院2064例不可切除HCC患者。
- RFA组1568例,SBRT组496例;倾向评分匹配后每组313例。
- 中位随访27.7个月。
主要发现
- 基线时SBRT组临床特征更不利:BCLC B-C期65% vs. 16%,中位肿瘤大小3.0cm vs. 1.9cm,既往肝脏定向治疗史81% vs. 49%(均p<0.001)。
- 3年累积局部复发率SBRT组21.2%,RFA组27.9%(p<0.001)。
- 调整临床因素后,SBRT与更低的局部复发风险相关:全队列HR 0.45(p<0.001),匹配队列HR 0.36(p<0.001)。
- 亚组分析显示SBRT在小肿瘤(≤3cm,无论位置)、膈下大肿瘤及TACE后进展者中局部控制更优。
- 急性≥3级毒性发生率SBRT组1.6%,RFA组2.6%(p=0.268)。
临床怎么用
- 对于不可切除HCC,尤其肿瘤>3cm位于膈下或TACE后进展者,可考虑SBRT作为RFA的替代。
- 当预估RFA后局部复发或毒性风险较高时,SBRT是应纳入考虑的选择。
局限性
- 回顾性研究设计,存在选择偏倚可能。
- SBRT组基线临床特征较RFA组更不利,虽经倾向评分匹配调整,仍可能存在未测量混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Few studies have been conducted to compare the efficacies of stereotactic body radiation therapy (SBRT) and radiofrequency ablation (RFA). Thus, in this multinational study, we compared the effectiveness of SBRT and RFA in patients with unresectable HCC. METHODS: The retrospective study cohort included 2,064 patients treated in 7 hospitals: 1,568 and 496 in the RFA and SBRT groups, respectively. More than half of the patients (56.5%) developed recurrent tumors, mainly after transarterial chemoembolization (44.8%). Propensity score matching was performed to adjust for clinical factors (n = 313 in each group). RESULTS: At baseline, the SBRT group had unfavorable clinical features compared to the RFA group, including BCLC stage (B-C 65% vs. 16%), tumor size (median 3.0 cm vs. 1.9 cm), and frequent history of liver-directed treatment (81% vs. 49%, all p <0.001). With a median follow-up of 27.7 months, the 3-year cumulative local recurrence rates in the SBRT and RFA groups were 21.2% and 27.9%, respectively (p <0.001). After adjusting for clinical factors, SBRT was related to a significantly lower risk of local recurrence than RFA in both the entire (hazard ratio [HR] 0.45, p <0.001) and matched (HR 0.36, p <0.001) cohorts. In subgroup analysis, SBRT was associated with superior local control in small tumors (≤3 cm) irrespective of location, large tumors located in the subphrenic region, and those that progressed after transarterial chemoembolization. Acute grade ≥3 toxicities occurred in 1.6% and 2.6% of the SBRT and RFA patients, respectively (p = 0.268). CONCLUSIONS: SBRT could be an effective alternative to RFA for unresectable HCC, particularly for larger tumors (>3 cm) in a subphrenic location and tumors that have progressed after transarterial chemoembolization. LAY SUMMARY: It is currently not known what the best treatment option is for patients with unresectable hepatocellular carcinoma. Here, we show that stereotactic body radiation therapy provides better local control than radiofrequency ablation, with comparable toxicities. Stereotactic body radiation therapy appears to be an effective alternative to radiofrequency ablation that should be considered when there is a higher risk of local recurrence or toxicity after radiofrequency ablation.
引用
- Kim N, Cheng J, Jung I, et al. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma. J Hepatol. 2020. PMID: 32165253. doi:10.1016/j.jhep.2020.03.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。